- Home
- SELF vs CUE Comparison
SELF vs CUE Comparison
Compare SELF & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SELF | CUE |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 49.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SELF | CUE |
|---|---|---|
| Price | $5.05 | $0.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 49.2K | ★ 666.5K |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | ★ 5.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $12,733,279.00 | $7,100,000.00 |
| Revenue This Year | $1.59 | $36.58 |
| Revenue Next Year | $1.62 | $32.10 |
| P/E Ratio | $32.13 | ★ N/A |
| Revenue Growth | ★ 3.36 | N/A |
| 52 Week Low | $4.73 | $0.24 |
| 52 Week High | $5.89 | $1.75 |
Technical Indicators
Market Signals| Indicator | SELF | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 57.28 | 13.49 |
| Support Level | $4.95 | $0.24 |
| Resistance Level | $5.18 | $0.51 |
| Average True Range (ATR) | 0.13 | 0.04 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 90.91 | 3.09 |
Price Performance
Historical ComparisonAbout SELF Global Self Storage Inc.
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.